



UGT1A9 mouse mAb

Catalog No BYmab-07897 Isotype IgG Reactivity Human; Mouse Applications WB Gene Name UGT1A9 GNT1 UGT1 Protein Name UGT1A9 Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1-9) (UGT1-09) (UGT1.9) (UGT1.9) (UDP-glucuronosyltransferase 1-4) (IugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity Ilsoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. Ilsoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Ilsoform 3]: Expressed in liver, kidney, co		
Reactivity Human; Mouse Applications WB Gene Name UGT1A9 GNT1 UGT1 Protein Name UGT1A9 Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1-9) (UGT1-09) (UGT1.9) (UDP-glucuronosyltransferase 1-9) (IugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity Ilsoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Ilsoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. 3 laternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, calatynic activity: UDP-	Catalog No	BYmab-07897
Applications Gene Name UGT1A9 GNT1 UGT1 Protein Name UGT1A9 Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-11) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-11) (UGT1) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-11) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-11) (UGT-11) (UGT-11) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-	Isotype	IgG
Gene Name UGT1A9 GNT1 UGT1 Protein Name UGT1A9 Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1-9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT-11) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Internative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronate and should be considered as preliminary data, disease: Defects in UGT1A1 are the cause of Crigler-Najiar syndrome type I	Reactivity	Human; Mouse
Protein Name UGT1A9 Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UgT-1l) (UGT-1l) (UGT-1l) (UDP-glucuronosyltransferase 1-9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal do	Applications	WB
Immunogen Synthesized peptide derived from human UGT1A9 AA range: 390-440 Specificity This antibody detects endogenous levels of UGT1A9 at Human/Mouse Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1-9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UgT-11) (UGT-11) (UGT-11) (UDP-glucuronosyltransferase 1-9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine step in the support of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products. A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity:UDP-glucurona	Gene Name	UGT1A9 GNT1 UGT1
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT11) (UDP-glucuronosyltransferase 1-1) (UGT-11) (UGT11) (UDP-glucuronosyltransferase 1-1) (Light 1) Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Ilsoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside, caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, diseases: Defects in UGT 14A1 are the cause of Crigler-Najiar syndro	Protein Name	UGT1A9
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UGT-1l) (UGT1l) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein . Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Ilsoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms are broduced. Isoforms produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms are produced. Isoforms are produced. Isoforms of 245 residues catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside, caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT141 are the cause of Crigler-Najiar syndrome type I	Immunogen	Synthesized peptide derived from human UGT1A9 AA range: 390-440
Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UGT-11) (UGT11) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 2]: expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 2]: expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 2]: expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 2]: expressed in liver, kidney, colon, esophagus and small intestine. ; lisoform 3 alternative products: A number of isoforms may be produced. Soforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronside, caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT 1A1 are the cause of Crigler-Najiar s	Specificity	This antibody detects endogenous levels of UGT1A9 at Human/Mouse
Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-I) (UGT-1I) (UGT-II) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Ilsoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, calleting to common C-terminal domain of 245 residues, calleting to under the sequence shown here is derived from an Ensemble automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT1A1 are the cause of Crigler-Naijar syndrome type I	Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.11% sodium azide.
affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UGT-1l) (UGT-1l) (UDP-glucuronosyltransferase 1-l) (UGT-1l) (UGT-1l) (UDP-glucuronosyltransferase 1-l) (UGT-1l) (UGT-1l) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus and small intestine. † Isoform 2]: Expressed in liver, kidney colon, esophagus an	Source	Monoclonal, Mouse,lgG
Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (UGT-11) (UDP-glucuronosyltransferase 1-I) (UGT-1I) (UGT-1I) (UGT1I) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside, caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Purification	
Purity ≥90% Storage Stability -20°C/1 year Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-I) (UGT-1I) (UGT1I) (UDP-glucuronosyltransferase 1-A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane ; Single-pass membrane protein . Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine. ; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside, caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT1A1 are the cause of Crigler-Naijar syndrome type I	Dilution	WB 1:500-2000
Storage Stability -20°C/1 year UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-l) (UGT-1l) (UGT-1l) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catallytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Concentration	1 mg/ml
Synonyms UDP-glucuronosyltransferase 1-9 (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-I) (UGT-II) (UGT1I) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Endoplasmic reticulum membrane; Single-pass membrane protein. Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; [Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine.; alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data, disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Purity	≥90%
(EC 2.4.1.17) (UDP-glucuronosyltransferase 1-I) (UGT-II) (UGTII) (UDP-glucuronosyltransferase 1A9) (lugP4) Observed Band 75kD Endoplasmic reticulum membrane; Single-pass membrane protein. [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Storage Stability	-20°C/1 year
Cell Pathway Endoplasmic reticulum membrane; Single-pass membrane protein. [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Synonyms	(EC 2.4.1.17) (UDP-glucuronosyltransferase 1-I) (UGT-1I) (UGT1I)
Tissue Specificity [Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; [Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Observed Band	75kD
[Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine. Function alternative products: A number of isoforms are produced. The different isozymes have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Cell Pathway	Endoplasmic reticulum membrane ; Single-pass membrane protein .
have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I	Tissue Specificity	[Isoform 1]: Expressed in liver, kidney, colon, esophagus and small intestine.; [Isoform 2]: Expressed in liver, kidney, colon, esophagus and small intestine.
	Function	have a different N-terminal domain and a common C-terminal domain of 245 residues, alternative products: A number of isoforms may be produced. Isoforms have a different N-terminal domain and a common C-terminal domain of 245 residues, catalytic activity: UDP-glucuronate + acceptor = UDP + acceptor beta-D-glucuronoside., caution: The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data., disease: Defects in UGT1A1 are the cause of Crigler-Najjar syndrome type I

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658



国内优质抗体供应商 精准的 WB 检测服务 24H 在线服务,欢迎咨询



	die of kernicterus (bilirubin accumulation in the basal ganglia and brainstem nuclei) within the first year of life. CN-I inheritance is autosomal recessive.,disease:Defects in UGT1A1 are the cause of Crigler-Najjar syn
Background	This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenols. [provided by RefSeq, Jul 2008],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images Western Blot analysis of various cells using UGT1A9 1 mouse mAb kDa 180 ---140 --100 --UGT1A9 75 --60 --45 ---35 --25 --15 --10 --

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658